1040P Nivolumab or atezolizumab in the second-line treatment of advanced non-small-cell lung cancer? Prognostic index based on real-world data

1040P Nivolumab or atezolizumab in the second-line treatment of advanced non-small-cell lung cancer? Prognostic index based on real-world data

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 33; p. S1030
Main Authors: Knetki-Wroblewska, M., Płużański, A., Tabor, S., Winiarczyk, K., Zaborowska-Szmit, M., Zajda, K., Janowicz Zebrowska, A., Piórek, A., Badurak, P., Jaśkiewicz, P., Kowalski, D.M., Krzakowski, M.J.
Format: Journal Article
Language:English
Published: 01-09-2022
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
DOI:10.1016/j.annonc.2022.07.1166